Academic Lead: Prof. Andreas Meyer-Lindenberg, Zentralinstitut fuer Seelische Gesundheit (Central Institute of Mental Health), Germany
EFPIA Lead: Dr. Adam Schwarz, Eli Lilly and Company Limited, US
This workpackage brings together academic partners with unique expertise in translational imaging with industry expertise in therapy research for schizophrenia and depression. Specific interests and expertise of GSK in the domain of human cognitive neuroimaging will dovetail with the academic interests in using these paradigms for the delineation of prefrontal-subcortical risk mechanisms. Both GSK and Roche have large expertise in rodent neuroimaging at 4.7 Ts and ASL that will combine.